Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GOOD-WP2: linagliptin versus repaglinide in older adults with type 2 diabetes at risk of sarcopenia
2018-000359-42Phase 4Completed
- Sponsor
- Policlinico Gemelli
- Start
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in type 2 diabetes mellitus (T2DM) comparing Linagliptin plus metformin with Repaglinide plus metformin (2 arms). Primary endpoints: Change in muscle strength, Change in physical function and 1 more. Started Feb 2021; status: completed.
02
Drugs
linagliptinrepaglinide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2018-000359-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000359-42.